Biogen Inc (MIL:1BIIB)
€ 141.3 0 (0%) Market Cap: 20.87 Bil Enterprise Value: 25.62 Bil PE Ratio: 13.49 PB Ratio: 1.33 GF Score: 53/100

Biogen Inc Evaluation Of Aducanumab Efficacy And Safety In Early Alzheimer's Disease Discussion at AD/PD Conference Call Transcript

Mar 13, 2021 / 11:45AM GMT
Randall J. Bateman

We're going to be discussing the amyloid beta targeting therapies in Alzheimer's disease session 2. I'm Randy Bateman. I'm a Professor of Neurology at Washington University and the Director of The Dominantly Inherited Alzheimer's Network and Trials Unit. Chad?

Chad Swanson

Hi, everybody. I'm Chad Swanson in the Neurology Business Group at Eisai and Clinical Development, and I am the international project team leader for aducanumab or BAN24 (sic) [BAN2401].

Randall J. Bateman

Great. And Mark?

Mark A. Mintun

I'm Mark Mintun, and I head the Alzheimer's disease development area for Eli Lilly and Company.

Randall J. Bateman

Great. And Samantha?

Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development

Hi there. Good morning, good afternoon. I'm Samantha Budd. I work at Biogen, and I head up the Neurodegeneration Development group. Thank you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot